Improvement of High-Density Lipoprotein Function in Patients With Early Rheumatoid Arthritis Treated With Methotrexate Monotherapy or Combination Therapies in a Randomized Controlled Trial Academic Article uri icon

Overview

MeSH Major

  • Antirheumatic Agents
  • Arthritis, Rheumatoid
  • Etanercept
  • Hydroxychloroquine
  • Lipoproteins, HDL
  • Methotrexate
  • Sulfasalazine

abstract

  • Reduced disease activity in patients with early RA treated with MTX monotherapy, MTX + ETN combination therapy, or MTX + SSZ + HCQ triple therapy in the TEAR trial was associated with improvements in the HDL function profile. Additional studies are warranted to evaluate abnormal HDL function as a potential mechanism and therapeutic target for CV risk in patients with RA.

publication date

  • January 2017

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC5195879

Digital Object Identifier (DOI)

  • 10.1002/art.39833

PubMed ID

  • 27483410

Additional Document Info

start page

  • 46

end page

  • 57

volume

  • 69

number

  • 1